ARVN · Arvinas, Inc.

0001628280-26-033669

Summary

Revenue collapsed 91.7% YoY as prior-year collaboration milestones did not repeat, driving a net loss of $57.6M, though cost restructuring narrowed operating cash burn.

Key takeaways

Revenue was $15.6M (-91.7% YoY) due to the absence of prior-year collaboration milestones.
Operating income swung to -$63.8M from $71.4M, reflecting the revenue decline and cost restructuring.
Net income was -$57.6M (-169.5% YoY), driven by the operating loss and lower interest income.
Diluted EPS was -$0.90, compared to $1.14 in the prior year.
Operating cash burn improved to -$69.2M from -$88.9M, aided by workforce reductions and cost optimization.
Cash, cash equivalents and marketable securities are expected to fund operations into the second half of 2028.

Full analysis

Revenue Collapse and the Pfizer Milestone Gap

Profitability Swing and Cost Discipline

Cash Flow and Liquidity Position

Pipeline Progress and Strategic Outlook

The company continues to advance its preclinical and clinical development programs. Regulatory plans for VEPPANU will be determined by the selected commercialization partner. The company expects to incur increasing operating losses as it progresses its product candidates.